Lupin announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility
in March 2022. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
